|
Bibliografía
|
1)
|
Baslaim M., Bakheet S., Bakheet R., Ezzat A., El-Foudeh M, Tulbah A. 18-Fluorodeoxyglucose-Positron Emission Tomography in Inflammatory Breast Cancer. World J. Surg. (2003); 27: 1099-1104.
|
|
2)
|
Biersack HJ, Palmedo H. Locally advanced breast cancer: is PET useful for monitoring primary chemotherapy?.J Nucl Med. 2003 Nov;44(11):1815-7
|
|
3)
|
Czernin J. FDG-PET in Breast Cancer: A different view of its clinical usefulness. Mol Imag Biol 2002; 4 : 35-45.
|
|
4)
|
Flanagan FL.; Dehdasti F., Siegel BA. PET in breast cancer. Semin Nucl Med, 1998; 28: 290-302.
|
|
5)
|
Grahek D., Montravers F., Kerrou K., Aide N., Lotz J-P., Talbot J-N. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging (2004); 31: 179-188.
|
|
6)
|
Goerres GW, Michel SC, Fehr MK, Kaim AH, Steinert HC, Seifert B, von Schulthess GK, Kubik-Huch RA. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol. 2003 Jul;13(7):1635-44.
|
|
7)
|
Hoh CK., Schiepers C. 18-FDG imaging in breast cancer. Semin Nucl Med, 1999; 29: 49-56.
|
|
8)
|
Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res. 2003 Mar-Apr;23(2C):1859-67.
|
|
9)
|
Stafford SE., Gralow JR., Schubert EK., Rinn KJ., Dunnwald LK., BS, CNMT, Livingston RB., Mankoff DA. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9: 913-921.
|
|
10)
|
Vranjesevic D., Schiepers C., Silverman D., Quon A., Villalpando J., Dahlbom M., Phelps ME., Czernin J. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 2003; 44: 1238-1242.
|
|
|
